(S)-3-氨基-2-((叔丁氧基羰基)氨基)丙酸甲酯盐酸盐 | 181228-33-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-3-氨基-2-((叔丁氧基羰基)氨基)丙酸甲酯盐酸盐
• 中文别名: 3-氨基-N-BOC-L-丙氨酸甲酯盐酸盐
• 英文名称: 3-amino-N-(tert-butoxycarbonyl)-L-alanine methyl ester hydrochloride
• 英文别名: (S)-Methyl 3-amino-2-((tert-butoxycarbonyl)amino)propanoate hydrochloride；methyl (2S)-3-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate;hydrochloride
• CAS: 181228-33-1
• 化学式: C₉H₁₈N₂O₄*ClH
• 分子量: 254.714
• InChiKey: IKRXWXBVGWAKNK-RGMNGODLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.43
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  储存温度为2-8°C，并需保存在惰性气体中。

制备方法与用途

3-氨基-2-((叔丁氧羰基)氨基)丙酸甲酯盐酸盐是一种丙氨酸衍生物[1]。

反应信息

• 作为反应物：
  描述：

  (S)-3-氨基-2-((叔丁氧基羰基)氨基)丙酸甲酯盐酸盐 在 O-<[cyano(ethoxycarbonyl)methylene]amino>-1,1,3,3-tetramethyluronium tetrafluoroborate 、 水 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.08h， 生成 ((S)-2-azepan-1-yl-1-{[(5-chloro-thiophene-2-carbonyl)-amino]-methyl}-2-oxo-ethyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  [EN] CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN
  [FR] CHLOROTHIOPHÈNE-AMIDES UTILISÉS COMME INHIBITEURS DES FACTEURS DE COAGULATION XA ET DE LA THROMBINE

  摘要：

  本发明涉及具有式I的化合物，其中R1; R2; R3; R4; R5, R13, R16, X和M具有权利要求中所指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强大的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶因子Xa（FXa）和凝血酶的可逆抑制剂，通常可应用于存在因子Xa和/或凝血酶不良活性的情况，或者用于治疗或预防需要抑制因子Xa和凝血酶的情况。此外，本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

  公开号：

  WO2009103440A1

文献信息

• METHOD FOR PRODUCING ALKYLAMINE DERIVATIVE AND ITS PRODUCTION INTERMEDIATE OF ALKYLAMINE DERIVATIVE
  申请人：AJINOMOTO CO., INC.

  公开号：US20180079715A1

  公开（公告）日：2018-03-22

  A method for producing an alkylamine derivative having a urea bond represented by formula (I), or a salt thereof, comprises the following steps (a) and (b), step (a): and step (b): deprotecting as necessary the reaction product obtained in step (a). The production method suitable for industrialization of the alkylamine derivative having a urea bond represented by formula (I), which is a compound highly useful as an agent having CaSR agonist effects is provided.

  生产具有由化学式（I）表示的脲键的烷基胺衍生物或其盐的方法包括以下步骤（a）和（b），步骤（a）：和步骤（b）：必要时去保护步骤（a）中获得的反应产物。提供了适用于工业化的生产方法，用于具有CaSR激动剂效果的剂的烷基胺衍生物，其具有由化学式（I）表示的脲键，这是一种非常有用的化合物。
• Fluorescent Peptides Labeled with Environment-Sensitive 7-Aminocoumarins and Their Interactions with Lipid Bilayer Membranes and Living Cells
  作者：Tokiko Murase、Toshitada Yoshihara、Keiichi Yamada、Seiji Tobita

  DOI：10.1246/bcsj.20120314

  日期：2013.4.15

  The photophysical properties of protected nonnatural amino acids Boc–l-Dap(7DEAC)–OMe (7DEAC: 7-diethylaminocoumarin) and Boc–l-Dap(C343)–OMe (C343: coumarin 343) were investigated to evaluate the suitability of these amino acids as fluorescent units in peptide-based fluorescent biosensors. The absorption and fluorescence spectra of Boc–l-Dap(7DEAC)–OMe and Boc–l-Dap(C343)–OMe exhibited significant red shifts with increasing solvent polarity. The fluorescence quantum yield and lifetime of Boc–l-Dap(7DEAC)–OMe solutions decreased remarkably with increasing solvent polarity, whereas those of Boc–l-Dap(C343)–OMe were slightly affected by the solvent polarity. Fluorescent peptides H–Dap(7DEAC)–LLA–OMe (1), H–Dap(7DEAC)–KLA–OMe (2), and H–Dap(7DEAC)–ELA–OMe (3) labeled with environment-sensitive 7DEAC were synthesized to examine the interactions of these labeled peptides with lipid membranes and living cells. Neutral 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and anionic 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG) liposomes were used to investigate peptide–membrane interactions. Hydrophobic peptide 1 exhibited high affinities to both DMPC and DMPC/DMPG mixed membranes. Of the three peptides, cationic peptide 2 exhibited the strongest affinity to DMPC/DMPG membranes, whereas anionic peptide 3 showed a much lower affinity to DMPC/DMPG membranes. These results could be interpreted based on hydrophobic and electrostatic interactions between the peptides and membranes. Peptide 1 was efficiently internalized into HeLa cells, whereas peptides 2 and 3 showed a much lower intracellular delivery.

  研究了受保护的非天然氨基酸Boc–l-Dap(7DEAC)–OMe (7DEAC: 7-二乙基氨基香豆素)和Boc–l-Dap(C343)–OMe (C343: 香豆素343)的光物理性质,以评估这些氨基酸作为肽基荧光生物传感器的荧光单元的适用性。Boc–l-Dap(7DEAC)–OMe和Boc–l-Dap(C343)–OMe的吸收和荧光光谱随着溶剂极性的增加呈现出显著的红移。Boc–l-Dap(7DEAC)–OMe溶液的荧光量子产率和寿命随着溶剂极性的增加显著降低,而Boc–l-Dap(C343)–OMe的荧光量子产率和寿命受溶剂极性的影响较小。合成了标记有环境敏感的7DEAC的荧光肽H–Dap(7DEAC)–LLA–OMe (1)、H–Dap(7DEAC)–KLA–OMe (2)和H–Dap(7DEAC)–ELA–OMe (3),以检查这些标记肽与脂质膜和活细胞的相互作用。使用中性的1,2-二肉豆蔻酰-sn-甘油-3-磷酸胆碱(DMPC)和阴离子的1,2-二肉豆蔻酰-sn-甘油-3-[磷酸-rac-(1-甘油)] (DMPG)脂质体来研究肽-膜相互作用。疏水性肽1对DMPC和DMPC/DMPG混合膜表现出高亲和力。在这三种肽中,阳离子肽2对DMPC/DMPG膜表现出最强的亲和力,而阴离子肽3对DMPC/DMPG膜的亲和力要低得多。这些结果可以根据肽和膜之间的疏水性和静电相互作用来解释。肽1被有效地内化到HeLA细胞中,而肽2和3的细胞内递送要低得多。
• PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF
  申请人：VivaVisionShanghaiLtd

  公开号：US20200131206A1

  公开（公告）日：2020-04-30

  The present invention provides a phosphorus-containing compound characterized by being a compound represented by the following structure: the compound is a novel immune cell migration inhibitor. The compound has good hydrophilicity and can be developed into eye drops. The compound has a strong inhibitory ability to immune cell migration and can relieve the symptoms of most dry-eye patients.

  本发明提供一种含磷化合物，其特征在于其为以下结构所代表的化合物：该化合物是一种新型的免疫细胞迁移抑制剂。该化合物具有良好的亲水性，可以开发成眼药水。该化合物对免疫细胞迁移具有强烈的抑制能力，可以缓解大多数干眼症患者的症状。
• CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN
  申请人：FOLLMANN Markus

  公开号：US20110112075A1

  公开（公告）日：2011-05-12

  The present invention relates to compounds of the formula I, wherein R1; R2; R3; R4; R5, R13, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and thrombin and can in general be applied in conditions in which an undesired activity of factor Xa and/or thrombin are present or for the cure or prevention of which an inhibition of factor Xa and thrombin are intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R1; R2; R3; R4; R5，R13，R16，X和M具有所述权利要求中指示的含义。式I的化合物是有价值的药理活性化合物。它们具有强烈的抗血栓作用，例如，它们适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血凝酶酶因子Xa（FXa）和凝血酶的可逆抑制剂，并且通常可以应用于存在因子Xa和/或凝血酶不良活性或为治愈或预防而意图抑制因子Xa和凝血酶的情况。此外，本发明还涉及式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制剂。
• Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin
  申请人：Follmann Markus

  公开号：US08378092B2

  公开（公告）日：2013-02-19

  The present invention relates to compounds of the formula I, wherein R1; R2; R3; R4; R5, R13, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and thrombin and can in general be applied in conditions in which an undesired activity of factor Xa and/or thrombin are present or for the cure or prevention of which an inhibition of factor Xa and thrombin are intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1；R2；R3；R4；R5，R13，R16，X和M具有所述权利要求中指示的含义。公式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它们是血凝酶因子Xa（FXa）和凝血酶的可逆抑制剂，通常可用于存在因子Xa和/或凝血酶不良活性或预防其发生的情况，或用于治疗或预防需要抑制因子Xa和凝血酶的情况。本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。